Share

Ebola

Johnson & Johnson’s Response to the DRC Crisis

  • The Democratic Republic of Congo (DRC) is currently facing the world’s second-largest Ebola outbreak on record. More than 3,000 cases, including more than 2,000 deaths, have been reported in the current outbreak to date, making it second only to the 2014-2016 West Africa epidemic.
  • As part of an expanded public health response, the DRC has decided to introduce Janssen’s investigational vaccine alongside other tools. A number of global health organizations, in collaboration with DRC stakeholders, will work closely to provide the vaccine beginning in November 2019.
  • Janssen has committed to donate up to 500,000 vaccine regimens in support of the initiative.
  • In line with recent recommendations from the Strategic Advisory Group of Experts (SAGE) on Immunization, the new vaccination initiative in the DRC will offer the Janssen investigational vaccine regimen to individuals at some risk of Ebola infection who live in areas close to the current outbreak zone, with the goal of preventing the further geographic spread of the virus.
The first batches of vaccine have been shipped to the DRC.

We have a responsibility as a leading global healthcare company to do all we can to address this urgent unmet medical need.

Developing effective Ebola vaccines will be critical if we are to combat outbreaks of this disease and protect frontline healthcare workers as well as the families and friends of Ebola victims.

We recognize the urgency of the situation and the need to collaborate with multiple partners to develop preventive solutions for Ebola.

While recognizing this is an investigational vaccine still in development, we have taken pandemic preparedness steps with the goal of ensuring that the world is better equipped for Ebola outbreaks.

About Janssen’s Ebola Vaccine Regimen

expand

The investigational preventive Ebola vaccine regimen in development at the Janssen Pharmaceutical Companies of Johnson & Johnson:

  • Consists of two doses leveraging different vaccines (Ad26.ZEBOV and MVA-BN-Filo).
  • Is well tolerated and induces robust and durable immune responses to the Ebola virus Zaire strain—the cause of the DRC outbreak.

Johnson & Johnson has built a stockpile of up to 1.5 million investigational Ebola vaccine regimens for potential use in public health emergencies.

expand

Ebola: A Timeline

The Ebola virus was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo (DRC). Over the past 40 years, there have been multiple Ebola outbreaks. The worst to date was the West African Ebola epidemic, which caused nearly 30,000 cases and more than 11,000 deaths in 2014-2016. The world’s second-largest outbreak is currently underway in the DRC.

2002

Janssen begins Ebola vaccine research program with NIH support

2014

· West Africa Ebola outbreak begins; declared international health emergency
· J&J commits to accelerate development and expand production of an Ebola vaccine

2015

· Announcement of IMI-supported consortia; start of Phase 1 clinical trials in the UK and US
· "EBOVAC-Salone" study begins in Sierra Leone. Additional Phase 3 studies start in US

2016

· First clinical data for Ebola vaccine regimen published in JAMA

2017

· First long-term clinical data published in JAMA
· Second partnership with BARDA to support U.S. licensure of vaccine

2018

Second-largest Ebola outbreak begins in DRC

2019

· WHO supports SAGE recommendation to evaluate Janssen vaccine in DRC
· J&J announces it will provide up to 500,000 regimens of Janssen vaccine for DRC clinical study
· Janssen files for European approval of vaccine regimen

2002

2014

2015

2016

2017

2018

2019

Working in Partnership

Johnson & Johnson has made a significant investment in the Janssen Ebola vaccine development program. We have also forged strategic partnerships with a wide range of the world’s leading scientific and medical research organizations to accelerate our progress.

expand

Commitment to Pandemic Preparedness

Johnson & Johnson is one of the few innovative healthcare companies that is actively engaged on pandemic preparedness and response.

expand

Through our Janssen Pharmaceutical Companies, we are developing new vaccines and/or treatments to combat infectious diseases that:

  • Are already pandemics, such as HIV, hepatitis B and tuberculosis (TB)
  • Or have pandemic potential, including Ebola, Zika and influenza
A look back at Johnson & Johnson’s response to the 2014-2016 Ebola epidemic in West Africa

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue